2026-10-23T17:52:00Zhttps://gumushane-rdlopen.rawdatalibrary.net/oai/request

oai:gumushane-rdlopen.rawdatalibrary.net:gumushane/164442026-10-22T11:41:02Zopenairecom_gumushane_10000col_gumushane_10001

Predicting hospitalization by TAPSE/SPAP and the role of spironolactone in asymptomatic heart failure patientsAydinyilmaz, FarukGuliyev, IlkinÖzbeyaz, Nail B.Algül, EnginAker, MertSahan, Haluk F.Erzurum, MuhammedFelekoglu, Mehmet A.Kalkan, Kamuranheart failure with reduced ejection fractionspironolactonesystolic pulmonary artery pressuretricuspid annular plane systolic excursionAim: To appraise the prediction of tricuspid annular plane systolic excursion (TAPSE)/systolic pulmonary artery pressure (SPAP) with regard to hospitalization and the effect of spironolactone use. Materials & methods: A total of 245 patients were evaluated for the study. Patients were followed for 1 year and cardiovascular outcomes were determined. Results: It was determined that TAPSE/SPAP was an independent predictor of hospitalization. A 0.1-mmHg decrease in TAPSE/SPAP was associated with a 9% increase in relative risk. No event was observed above the 0.47 level. Negative correlation with TAPSE (uncoupling) began in the spironolactone group when SPAP was >= 43 and in nonusers when SPAP was 38 (Pearson's correlation coefficient: -,731 vs -,383; p < 0.001 vs p = 0.037). Conclusion: TAPSE/SPAP measurement may be useful in predicting 1-year hospitalization in asymptomatic heart failure patients. This ratio was also found to be higher in patients who used spironolactone.TAYLOR & FRANCIS LTD2023-02Articlehttps://rdlopen.rawdatalibrary.net/r/gumushane/16444https://doi.org/10.2217/bmm-2022-07371752-0363enBIOMARKERS IN MEDICINEinfo:eu-repo/semantics/closedAccessinfo:eu-repo/semantics/articlehttps://gumushane-rdlopen.rawdatalibrary.net/tr/items/gumushane/16444